Angiopoietins as Potential Targets in Management of Retinal Disease

Arshad M Khanani,1,2 Matthew W Russell,3,4 Aamir A Aziz,1,2 Carl J Danzig,5,6 Christina Y Weng,7 David A Eichenbaum,8,9 Rishi P Singh3,4 1Sierra Eye Associates, Reno, NV, USA; 2The University of Nevada, Reno School of Medicine, Reno, NV, USA; 3Center for Ophthalmic Bioinformatics, Cole Eye Institute...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	ang/tie faricimab yosemite rhine tenaya lucerne Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2dbb17760b0148fd9c76775d32c643de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2dbb17760b0148fd9c76775d32c643de
record_format	dspace
spelling	oai:doaj.org-article:2dbb17760b0148fd9c76775d32c643de2021-12-02T16:32:47ZAngiopoietins as Potential Targets in Management of Retinal Disease1177-5483https://doaj.org/article/2dbb17760b0148fd9c76775d32c643de2021-09-01T00:00:00Zhttps://www.dovepress.com/angiopoietins-as-potential-targets-in-management-of-retinal-disease-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Arshad M Khanani,1,2 Matthew W Russell,3,4 Aamir A Aziz,1,2 Carl J Danzig,5,6 Christina Y Weng,7 David A Eichenbaum,8,9 Rishi P Singh3,4 1Sierra Eye Associates, Reno, NV, USA; 2The University of Nevada, Reno School of Medicine, Reno, NV, USA; 3Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA; 4Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA; 5Rand Eye Institute, Deerfield, FLA, USA; 6Florida Atlantic University, Charles E. Schmidt College of Medicine, Boca Raton, FL, USA; 7Baylor College of Medicine, Houston, TX, USA; 8Retina Vitreous Associates of Florida, St Petersburg, FLA, USA; 9University of South Florida Morsani College of Medicine, Tampa, FLA, USACorrespondence: Arshad M Khanani 950 Ryland Street, Reno, NV, 89502, USATel +775 329-0286Fax +775-329-0849Email arshad.khanani@gmail.comAbstract: The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.Keywords: Ang/Tie, faricimab, YOSEMITE, RHINE, TENAYA, LUCERNEKhanani AMRussell MWAziz AADanzig CJWeng CYEichenbaum DASingh RPDove Medical Pressarticleang/tiefaricimabyosemiterhinetenayalucerneOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3747-3755 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ang/tie faricimab yosemite rhine tenaya lucerne Ophthalmology RE1-994
spellingShingle	ang/tie faricimab yosemite rhine tenaya lucerne Ophthalmology RE1-994 Khanani AM Russell MW Aziz AA Danzig CJ Weng CY Eichenbaum DA Singh RP Angiopoietins as Potential Targets in Management of Retinal Disease
description	Arshad M Khanani,1,2 Matthew W Russell,3,4 Aamir A Aziz,1,2 Carl J Danzig,5,6 Christina Y Weng,7 David A Eichenbaum,8,9 Rishi P Singh3,4 1Sierra Eye Associates, Reno, NV, USA; 2The University of Nevada, Reno School of Medicine, Reno, NV, USA; 3Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA; 4Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA; 5Rand Eye Institute, Deerfield, FLA, USA; 6Florida Atlantic University, Charles E. Schmidt College of Medicine, Boca Raton, FL, USA; 7Baylor College of Medicine, Houston, TX, USA; 8Retina Vitreous Associates of Florida, St Petersburg, FLA, USA; 9University of South Florida Morsani College of Medicine, Tampa, FLA, USACorrespondence: Arshad M Khanani 950 Ryland Street, Reno, NV, 89502, USATel +775 329-0286Fax +775-329-0849Email arshad.khanani@gmail.comAbstract: The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.Keywords: Ang/Tie, faricimab, YOSEMITE, RHINE, TENAYA, LUCERNE
format	article
author	Khanani AM Russell MW Aziz AA Danzig CJ Weng CY Eichenbaum DA Singh RP
author_facet	Khanani AM Russell MW Aziz AA Danzig CJ Weng CY Eichenbaum DA Singh RP
author_sort	Khanani AM
title	Angiopoietins as Potential Targets in Management of Retinal Disease
title_short	Angiopoietins as Potential Targets in Management of Retinal Disease
title_full	Angiopoietins as Potential Targets in Management of Retinal Disease
title_fullStr	Angiopoietins as Potential Targets in Management of Retinal Disease
title_full_unstemmed	Angiopoietins as Potential Targets in Management of Retinal Disease
title_sort	angiopoietins as potential targets in management of retinal disease
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/2dbb17760b0148fd9c76775d32c643de
work_keys_str_mv	AT khananiam angiopoietinsaspotentialtargetsinmanagementofretinaldisease AT russellmw angiopoietinsaspotentialtargetsinmanagementofretinaldisease AT azizaa angiopoietinsaspotentialtargetsinmanagementofretinaldisease AT danzigcj angiopoietinsaspotentialtargetsinmanagementofretinaldisease AT wengcy angiopoietinsaspotentialtargetsinmanagementofretinaldisease AT eichenbaumda angiopoietinsaspotentialtargetsinmanagementofretinaldisease AT singhrp angiopoietinsaspotentialtargetsinmanagementofretinaldisease
_version_	1718383800111595520

Angiopoietins as Potential Targets in Management of Retinal Disease

Ejemplares similares